Lombard Odier Asset Management (Switzerland)’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Lombard Odier Asset Management (Switzerland)’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-112,952	Closed	-$4.2M	–	395
2023 Q1	$4.2M	Buy	112,952 +42,999	+61%	+$1.93M	0.37%	75
2022 Q4	$3.17M	Buy	69,953 +2,439	+4%	+$158K	0.25%	89
2022 Q3	$4.71M	Sell	67,514 -8,231	-11%	-$609K	0.4%	58
2022 Q2	$5.08M	Buy	75,745 +36,653	+94%	+$2.33M	0.43%	59
2022 Q1	$3.21M	Sell	39,092 -82,644	-68%	-$8.45M	0.25%	75
2021 Q4	$17.9M	Buy	121,736 +28,579	+31%	+$4.44M	1.14%	35
2021 Q3	$16.5M	Buy	93,157 +19,447	+26%	+$3.13M	1.02%	41
2021 Q2	$11.9M	Buy	73,710 +30,282	+70%	+$4.86M	0.6%	65
2021 Q1	$7.44M	Buy	+43,428	New	+$8.6M	0.49%	67

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Lombard Odier Asset Management (Switzerland)'s MRTX Position: Q2 2023 in Review

Lombard Odier Asset Management (Switzerland) sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2023, closing a stake of 112,952 shares — an estimated $4.2M sold.

Lombard Odier Asset Management (Switzerland) first reported a position in MRTX in Q1 2021 and held it in 9 quarters. The position peaked at $17.9M in Q4 2021. 207 funds tracked by Wall St. Rank hold MRTX as of Q2 2023.

Lombard Odier Asset Management (Switzerland) reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Lombard Odier Asset Management (Switzerland) sold 112,952 Mirati Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $4.2M.
Lombard Odier Asset Management (Switzerland) first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2021 and held it in 9 quarters.
Lombard Odier Asset Management (Switzerland)'s Mirati Therapeutics, Inc. Common Stock position peaked at $17.9M in Q4 2021.
207 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Lombard Odier Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 14 Aug 2023.